Trials / Not Yet Recruiting
Not Yet RecruitingNCT06537674
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer
An Exploratory Clinical Study of the PRO of Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Jiangsu Famous Medical Technology Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
This study evaluated the clinical benefits of intravenous administration of pyrotinib combined with trastuzumab subcutaneous preparation by comparing the efficacy and quality of life of intravenous administration in the treatment of HER2-positive early breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab intravenous drip/Trastuzumab Subcutaneous Injection | Group A is Trastuzumab intravenous drip,Group B is Trastuzumab Subcutaneous Injection |
Timeline
- Start date
- 2024-08-15
- Primary completion
- 2025-12-30
- Completion
- 2026-12-30
- First posted
- 2024-08-05
- Last updated
- 2024-08-05
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06537674. Inclusion in this directory is not an endorsement.